Prothena Corp Public (PRTA) Equity Average (2013 - 2026)
Prothena Corp Public (PRTA) recorded quarterly Equity Average of $296.5 million in Q1 2026, up 3.06% quarter-over-quarter from $287.7 million in Q4 2025, and down 35.85% on a YoY basis from $462.3 million in Q1 2025.
Prothena Corp Public (PRTA) Equity Average (2013 - 2026) Analysis & Trends
Prothena Corp Public's Equity Average history runs 14 years deep, the most recent figure standing at $296.5 million for Q1 2026.
- In Q1 2026, Equity Average fell 35.85% year-over-year to $296.5 million; the TTM figure through Mar 2026 stood at $296.5 million (down 35.85% YoY), while the FY2025 annual figure was $383.7 million, down 26.8% from the prior year.
- Equity Average was $296.5 million for Q1 2026 at Prothena Corp Public, up from $287.7 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $614.7 million in Q1 2023 to a low of $287.7 million in Q4 2025.
- Historically, Equity Average has averaged $474.9 million across 5 years, with a median of $510.6 million in 2024.
- The sharpest annual moves came in 2022 and 2025: Equity Average soared 116.19% in 2022, then sank 44.52% in 2025.
- A 5-year view of Equity Average shows it stood at $513.3 million in 2022, then rose by 14.8% to $589.3 million in 2023, then dropped by 13.35% to $510.6 million in 2024, then slumped by 43.65% to $287.7 million in 2025, then climbed by 3.06% to $296.5 million in 2026.
- The last three Equity Average figures came in at $296.5 million (Q1 2026), $287.7 million (Q4 2025), and $309.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 21.35 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 516.41 Mn |
| 10 | Prothena Corp Public | 479.08 Mn | 149.61 Mn | - | 296.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 296.55 Mn |
| Dec 31, 2025 | 287.73 Mn |
| Sep 30, 2025 | 309.66 Mn |
| Jun 30, 2025 | 381.01 Mn |
| Mar 31, 2025 | 462.30 Mn |
| Dec 31, 2024 | 510.64 Mn |
| Sep 30, 2024 | 558.14 Mn |
| Jun 30, 2024 | 542.16 Mn |
| Mar 31, 2024 | 531.88 Mn |
| Dec 31, 2023 | 589.30 Mn |
| Sep 30, 2023 | 599.45 Mn |
| Jun 30, 2023 | 594.54 Mn |
| Mar 31, 2023 | 614.73 Mn |
| Dec 31, 2022 | 513.35 Mn |
| Sep 30, 2022 | 405.97 Mn |
| Jun 30, 2022 | 423.09 Mn |
| Mar 31, 2022 | 452.46 Mn |
| Dec 31, 2021 | 478.26 Mn |
| Sep 30, 2021 | 389.34 Mn |
| Jun 30, 2021 | 261.40 Mn |